Company Overview - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [3] - The company has proprietary ADC platforms, including Dolasynthen and Immunosynthen, which have led to a pipeline of product candidates aimed at treating various cancers [3] Upcoming Financial Results - Mersana Therapeutics will provide business updates and report its financial results for the third quarter ended September 30, 2025, on November 14, 2025 [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1] Accessing the Conference Call - Investors can access the conference call by dialing 833-255-2826 for domestic calls or 412-317-0689 for international calls [2] - A live webcast will be available on the company's website, with a replay accessible for approximately 90 days following the call [2]

Company Overview - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [3] - The company has proprietary platforms for cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADCs, leading to a pipeline of product candidates [3] Pipeline and Product Candidates - Mersana's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2) [3] Upcoming Financial Updates - Mersana Therapeutics will provide business updates and report its financial results for the second quarter ended June 30, 2025, on August 13, 2025 [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1]